Fig. 3
Characterization of amyloid-β (Aβ) secretion in control and Alzheimer’s disease induced pluripotent stem cell (AD iPSC)-derived neurons at terminal differentiation day 42 (TD42), TD56, and TD70. a The amount of secreted Aβ1–40 from control-, early-onset familial Alzheimer’s disease (fAD)- (fAD-1–fAD-4), and sporadic Alzheimer’s disease (sAD)- (sAD-1–sAD-6)-iPSC-derived neurons. b The amount of Aβ1–42 released from control- and AD-iPSC-derived neurons. c The ratio of Aβ1–42/Aβ1–40 from neurons derived from control and AD lines. Aβ1–40 and Aβ1–42 secreted from neural cells into the medium were measured at day 4 after the last medium change. The extracellular Aβ levels determined (in picomolar concentrations) were normalized to total protein content of cell lysates. Data represent mean ± SEM (n = 3). Dunnett’s test was performed to evaluate the significance of groups compared with control at the same time point of differentiation (*p < 0.05)